Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vtesse

Vtesse
2014 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
$200M LATEST DEAL AMOUNT
Description

Developer of new drug treatments designed to treat severe and life-threatening diseases. The company's new drug treatments, includes treatment for rare disease Niemann-Pick Disease Type C (NPC), enabling patients with NPC and other lysosomal storage diseases to get treated. It also offers information, resources and support that can be used to better understand NPC and to cope with its impact on lives.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Information Services (B2C)
Parent Company
Primary Office
  • 910 Clopper Road
  • Suite 220 South
  • Gaithersburg, MD 20878
  • United States

+1 (240) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vtesse’s full profile, request a free trial.

Vtesse Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 03-Apr-2017 $200M 0000 00000 Completed Startup
2. Early Stage VC (Series A) 25-Jul-2016 0000 0000 000.00 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Clinical Trials - Phase 2
To view this company’s complete deal history including valuation and funding, request access »

Vtesse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Vtesse Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intarcia Therapeutics Venture Capital-Backed Boston, MA 000 00.000 0000000000 0 00.000
00000 Venture Capital-Backed Pittsburgh, PA 00 000.00 0000000000 0 000.00
00000000 000000000 Pending Transaction (M&A) New York, NY 000000&0
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 000.00 00000000000 000.00
000000000 Venture Capital-Backed New York, NY 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

Vtesse Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Bay City Capital Venture Capital Minority 000 0000 000000 0
Cydan Accelerator/Incubator Minority 000 0000 000000 0
Lundbeckfond Ventures Corporate Venture Capital Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Vtesse Executive Team (6)

Name Title Board
Seat
Contact
Info
Ravi Rao Ph.D Chief Business Officer
Michael Massaro Vice President, Clinical Operations
Sarah Frech Vice President, Clinical Research
Allan Darling Ph.D Vice President, Technical Operations
Jason Meyenburg Chief Commercial Officer

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »